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Reply to V. Turan et al
We appreciate the interest of Turan et al1 in our sys-
tematic review and individual patient-level data meta-
analysis of randomized controlled trials (RCTs) that
explored the role of temporary ovarian suppression
with gonadotropin-releasing hormone agonists
(GnRHa) during chemotherapy as a strategy to pre-
serve ovarian function and fertility in premenopausal
patients with breast cancer.2
The authors consider the exclusion of RCTs in patients
with hematologic malignancies as a limitation of our
analysis; however, the decision to focus only on breast
cancer RCTs was based on both methodological and
clinical reasons. First, only 154 patients were included in
four RCTs for hematologic malignancies compared with
13 breast cancer RCTs that included 1,581 women.3,4
Second, women with hematologic malignancies or breast
cancer included in these RCTs were quite different in
terms of both age at diagnosis (ie, approximately 25 years
for hematologicmalignancies, 40 years for breast cancer)
and chemotherapy regimens used (ie, with high [eg,
conditioning regimens for hematopoietic stem-cell
transplantation] or low [eg, doxorubicin, bleomycin,
vinblastine, and dacarbazine] gonadotoxic potential for
hematologic malignancies, with intermediate gona-
dotoxicity [eg, cyclophosphamide-based regimens] for
breast cancer).3,4 With consideration that both the nu-
merical imbalance and the fact that age as well as type
of chemotherapy are the most important factors af-
fecting the risk of premature ovarian insufﬁciency
(POI),5 the RCTs that investigated GnRHa use during
chemotherapy in women with hematologic malignan-
cies or breast cancer should not be mixed. The use of
oral contraceptives during chemotherapy and oncologic
follow-up in several women treated for hematologic
malignancies adds complexity in the interpretation of
these RCTs.3
Turan et al1 raise additional concerns about the im-
possibility to collect individual patient-level data from
all the available breast cancer RCTs, the lack of sig-
niﬁcant reduction in amenorrhea risk 1 year after
chemotherapy completion, and the absence of data on
antimullerian hormone (AMH) levels.
As we have acknowledged,2 despite our efforts in trying
to obtain data from all RCTs, we were able to collect
individual patient-level data from the ﬁve major pub-
lished RCTs, including 55.2% of the potentially eligible
population (873 of 1,581). However, there was no
disproportional representation of positive and negative
RCTs included or not in our analysis2,4 (Table 1).
In addition and of note, our prior meta-analysis that
was based on abstracted data from all the available
breast cancer RCTs except for the OPTION (Ovarian
Protection Trial in Premenopausal Breast Cancer
Patients) study (a positive trial, which was not available
at the time)6 showed similar results to our present
analysis2,4 (Table 1). The only exception is represented
by 1-year amenorrhea for which a protective effect that
favors GnRHa administration during chemotherapy
was observed only when a larger number of RCTs was
included.2,4 Of note, our ﬁndings showing that ap-
proximately 15% of women resume menstrual func-
tion . 1 year after chemotherapy also support the
expert opinion–based deﬁnition of chemotherapy-
induced POI to be assessed not earlier than 2 years
after the end of cytotoxic therapy.7
We acknowledged the lack of AMH data as a limitation
to assess the gonadal protection of GnRHa use.2
However, three of the ﬁve included RCTs deﬁned POI
on the basis of not only post-treatment amenorrhea but
also postmenopausal levels of other ovarian function
parameters, such as follicle-stimulating hormone and
estradiol. Indeed, a composite end point that included
menstrual function and follicle-stimulating hormone
levels . 25 IU/L is the currently adopted deﬁnition of
POI.7,8 Moreover, although AMH plays an important role
in predicting oocyte yield after controlled ovarian
stimulation, recent studies have questioned its value as
amarker of chemotherapy-induced POI and infertility by
showing that both menstrual function resumption and
post-treatment pregnancies can be observed in women
with low AMH levels.3,9
We agree that the data on post-treatment pregnancies
are limited and that temporary ovarian suppression with
GnRHa during chemotherapy should not preclude the
access to oocyte/embryo cryopreservation. However, on
the basis of the observed signiﬁcantly higher pregnancy
rate for women treated with GnRHa,2 this strategy can
be offered as an adjunct for patients after cryopreser-
vation techniques to increase the chances of natural
conception as well for those who do not have access to
assisted reproductive options.
Moreover, preservation of ovarian function and
avoidance of its negative consequences and associ-
ated symptoms may represent another important goal
for premenopausal patients with breast cancer irre-
spective of their pregnancy desire and age at di-
agnosis. On the basis of our ﬁndings and as
recommended by current guidelines (including those
recently updated by ASCO),7,10,11 temporary ovarian
suppression with GnRHa during chemotherapy can
now be considered as a strategy to reduce the likeli-
hood of POI for premenopausal women in whom
continued ovarian function is desirable. Future well-
conducted in vitro and in vivo animal experiments in
species other than rodents should be encouraged to
explain the protective mechanism of action of GnRHa.
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TABLE 1. Comparison of Meta-Analyses of RCTs on the Role of Temporary Ovarian Suppression With GnRHas During Chemotherapy in
Premenopausal Patients With Breast Cancer
Meta-Analysis
Abstracted Data4 Individual Patient-Level Data2
No. of included RCTs 12 5
No. (%) of included RCTs with positive results 8 (67) 3 (60)
No. of included patients 1,231 873
POI per study primary end point deﬁnition
(GnRHa v control), OR (95% CI; P)
0.36 (0.23 to 0.57; , .001) 0.38 (0.26 to 0.57; , .001)
Amenorrhea 1 year after chemotherapy
(GnRHa v control), OR (95% CI; P)
0.55 (0.41 to 0.73; , .001) 0.92 (0.66 to 1.28; .623)
Amenorrhea 2 years after chemotherapy
(GnRHa v control), OR (95% CI; P)
— 0.51 (0.31 to 0.85; .009)
Post-treatment pregnancy
(GnRHa v control), OR (95% CI; P) 1.83 (1.02 to 3.28; .041) 1.83* (1.06 to 3.15; .030)
Disease-free survival
(GnRHa v control), HR (95% CI; P) 1.00 (0.49 to 2.04; .939) 1.01 (0.72 to 1.42; .999)
Overall survival
(GnRHa v control), HR (95% CI; P) — 0.67 (0.42 to 1.06; .083)
NOTE. Comparison between the largest meta-analysis on the basis of abstracted data and the current meta-analysis on the basis of individual
patient-level data of RCTs that explored the role of temporary ovarian suppression with GnRHa during chemotherapy as a strategy to preserve
ovarian function and fertility in premenopausal patients with breast cancer.
Abbreviations: GnRHa, gonadotropin-releasing hormone agonist; HR, hazard ratio; OR, odds ratio; POI, premature ovarian insufﬁciency; RCT,
randomized controlled trial.
*Incidence rate ratio.
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